CureDuchenne Ventures Invests in hC Bioscience and its Novel tRNA-Based Therapeutic Approach for Duchenne Muscular Dystrophy

“Our venture investments have successfully contributed to the development of life-changing therapies and technologies that aim to produce near-complete dystrophin, including exon skipping therapy and gene therapy,” said Debra Miller, founder and chief executive officer of CureDuchenne. “tRNA is another promising therapeutic approach that offers the potential to produce full-length functional dystrophin protein. This investment marks the start of a long-term relationship with hC Bioscience and allows us to further diversify the treatments we hope to help bring to patients.” 

See full press release HERE